FundedIQ
Biotechnology

Apogee Therapeutics

Apogee Therapeutics, a biotechnology company headquartered in San Francisco, California, was established in 2022 with a focus on developing innovative therapies for immunological and inflammatory conditions to meet the needs of patients.

apogeetherapeutics.com San Francisco, United States 251-500 employees
Total raised
$695M
Latest round: +101% of prior total
Rounds
2
Latest
Series Unknown
Mar 2026

Apogee Therapeutics, a biotechnology company headquartered in San Francisco, California, was established in 2022 with a focus on developing innovative therapies for immunological and inflammatory conditions to meet the needs of patients.

Apogee Therapeutics has raised $695M across 2 rounds. Its most recent round was a Series Unknown of $350M in Mar 2026. Full funding history, investors, and team are detailed below.

Funding history

2 rounds · 1 visible Unlock with plan

2 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
Mar 24, 2026
Series Unknown
$350M

Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Apogee Therapeutics is featured in

Similar companies

Ammortal

Ammortal is a healthcare services company that offers bio-optimization services.

Series Unknown $25.0M
Omniox

Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.

Series Unknown $24.1M
Swaza

Swaza develops nanotechnology-based therapeutics designed to address critical medical conditions involving impaired oxygen delivery and tissue healing. The company focuses on a nanofluid breathing aid, AeroHeal, which delivers oxygen and removes carbon dioxide in patients with compromised lungs, eliminating the need for invasive ventilation. Their primary product, SWAZA-1, is a non-invasive nanofluid that facilitates gas exchange in damaged lungs. Additionally, SWAZA-2 is an oxygen-enriched biomaterial aimed at enhancing wound healing, and SWAZA-3 is a thermoreversible enema intended for emergency oxygenation.

Seed $400k
Immusoft

A cell therapy business called Immusoft is dedicated to creating revolutionary treatments for uncommon diseases by leveraging sustained delivery of therapeutic proteins from a patient's own cells. Immune System Programming (ISPTM), a technology platform being developed by the company, alters a patient's B cells and teaches them to create gene-encoded medications. The ISP-reprogrammed B cells develop into tiny drug factories that are anticipated to live in patients for many years and give therapeutic effect. The business is based in Seattle, Washington.

Series Unknown $15.0M
Charlotte's Web
Series Unknown $74.4M
Centivax

Defeat the mutants.

Series Unknown $37.0M
Artelo Biosciences

Artelo Biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. Its programmes have the potential to dramatically improve patient care in major markets.

Series Unknown $11.0M
Zenas BioPharma

Zenas BioPharma is a company based in Florida, USA that specializes in creating immune-focused treatments for patients.

Series Unknown $100M
Vor Biopharma

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.

Series Unknown $75.0M
OnKure Therapeutics

OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of #cancer.

Series Unknown $150M
Rybodyn

Rybodyn is a biotechnology research company that develops therapeutics to train the immune system to detect and eradicate cancer internally.

Seed $10.0M
Turn Therapeutics

Turn Therapeutics is a pharmaceutical company that is dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics was founded to reduce antibiotic resistance through best-in-class acute and chronic wound care products. The company's mission is to leverage expertise in drug delivery to create disruptive products for high need indications. GLOBAL HEALTH SOLUTIONS, INC. , dba Turn Therapeutics.

Series Unknown $7.0M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.